Clinical trial
Combination Chemotherapy in Treating Patients With Breast Cancer
NCT00003088 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003088 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Breast Cancer |
| Official title | A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | cyclophosphamide, doxorubicin hydrochloride, paclitaxel |
| Enrollment | 2,005 |
| Start date | Sep 1, 1997 |
| Primary completion | Apr 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Sep 6, 2004 |
| Last update posted | Apr 29, 2020 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: